Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

25.68 -0.54

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.53

Massimo

25.72

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+53.05% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

737M

2.8B

Apertura precedente

26.22

Chiusura precedente

25.68

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 set 2026, 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, with a cumulative return of -2.04% since Saturday amid ongoing geopolitical instability affecting markets.

20 set 2026, 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, amid ongoing geopolitical instability related to the Middle East conflict affecting energy prices and markets.

20 set 2026, 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

20 set 2026, 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday's close, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

19 set 2026, 00:06 UTC

News

Hf Foods Group Inc. has terminated its $100 million equity offering program, with the stock declining in after-market trading following this decision.

19 set 2026, 00:02 UTC

News

Block Inc is facilitating Ideal Nutrition's expansion to at least 20 U.S. locations, contributing to a modest increase in its stock during after-market hours.

19 set 2026, 00:02 UTC

News
Social Media

MongoDB reported after-market earnings of $771.77 million and EPS of $1.90, exceeding estimates, with stock trading higher in line with market trends.

19 set 2026, 00:02 UTC

News
Social Media

Accenture PLC and Anthropic announced a partnership to invest $1 billion each in AI safety, driving a significant increase in Accenture's stock price in after-hours trading.

19 set 2026, 00:02 UTC

News

Shares lower in after-market as DOJ reviews antitrust lawsuit.

19 set 2026, 00:02 UTC

News
Correlated Moves

Corning Inc's stock is modestly lower in after-market trading, potentially influenced by ASML Holding, despite four consecutive higher daily closes leading into this session.

19 set 2026, 00:02 UTC

News

Kimberly-Clark Corp is higher in after-market trading following plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns.

19 set 2026, 00:01 UTC

News

S&P Global Inc is experiencing modest gains in after-market trading, recovering from an early dip while remaining below its 20-day moving average.

19 set 2026, 00:01 UTC

News

RTX Corp is seeing a modest decline in after-market trading, continuing a downward trend since Friday's close and remaining below its 20-day moving average.

19 set 2026, 00:01 UTC

News

Union Pacific Corp shares are trading lower in after-market hours, despite UBS upgrading its rating to Buy and raising the price target to $339.

18 set 2026, 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18 set 2026, 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18 set 2026, 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18 set 2026, 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18 set 2026, 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18 set 2026, 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18 set 2026, 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18 set 2026, 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18 set 2026, 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18 set 2026, 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18 set 2026, 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18 set 2026, 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18 set 2026, 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18 set 2026, 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18 set 2026, 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18 set 2026, 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

53.05% in crescita

Previsioni per 12 mesi

Media 39.333 USD  53.05%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.